Tri Voglidet 0.2/2 is a fixed-dose combination tablet designed for the therapeutic management of type 2 diabetes mellitus. The formulation integrates three active pharmaceutical ingredients: Glimepiride, a sulfonylurea that stimulates insulin secretion; Voglibose, an alpha-glucosidase inhibitor that delays carbohydrate absorption; and Metformin SR, a biguanide with improved insulin sensitivity and reduced hepatic glucose production. The sustained-release (SR) formulation of Metformin ensures prolonged therapeutic effect, minimizing peak-to-trough fluctuations. The tablet is manufactured using advanced direct compression techniques, incorporating excipients such as microcrystalline cellulose, magnesium stearate, and hydroxypropyl methylcellulose (HPMC) to ensure stability, uniformity, and controlled release. The combination of active ingredients is optimized to enhance bioavailability, reduce gastrointestinal side effects, and improve patient adherence. The formulation is designed to meet stringent pharmaceutical requirements for dissolution, disintegration, and content uniformity, ensuring consistent therapeutic performance.
Manufacturing Capability
Delwis Healthcare’s manufacturing infrastructure is equipped to produce high-quality combination tablets like Tri Voglidet 0.2/2 with precision and scalability. Our facility adheres to current Good Manufacturing Practices (cGMP) and employs state-of-the-art equipment, including high-speed tablet compression machines, fluid bed coating systems, and automated blending units. The production process for sustained-release formulations utilizes advanced coating technologies to ensure controlled drug release. Sterile processing capabilities are maintained through ISO Class 7 cleanroom environments, ensuring contamination-free manufacturing. The facility is designed for seamless scalability, enabling bulk production to meet global demand while maintaining consistent quality. Quality systems include real-time monitoring, process validation, and rigorous documentation to ensure compliance with regulatory standards.
Available Strengths and Packaging
Composition: Glimepiride 2mg + Voglibose 0.2mg + Metformin 500mg SR Tab
Packaging: 10x10 Blister
Tri Voglidet 0.2/2 is available in a fixed-dose combination strength of Glimepiride 2mg, Voglibose 0.2mg, and Metformin 500mg SR. The product is packaged in 10x10 blister packs, ensuring tamper-evidence, moisture resistance, and ease of distribution. The blister packaging format is ideal for retail and hospital settings, offering protection against environmental degradation while maintaining product integrity.
Contract Manufacturing / Third Party Manufacturing
Delwis Healthcare offers comprehensive contract manufacturing, private label, and third-party manufacturing services tailored to pharmaceutical buyers. Our capabilities include the production of combination tablets, sustained-release formulations, and custom packaging solutions. We provide end-to-end manufacturing support, from formulation development to final packaging, ensuring compliance with global regulatory standards. Our facility is equipped to handle small-scale prototyping and large-scale bulk production, making us a reliable partner for pharmaceutical companies seeking to launch new products. We also support private label manufacturing, enabling clients to brand and distribute products under their own names.
Quality Assurance
Quality assurance at Delwis Healthcare is built on rigorous testing, analytical validation, and adherence to international standards. Every batch of Tri Voglidet 0.2/2 undergoes comprehensive quality control checks, including dissolution testing, disintegration time analysis, and content uniformity assessments. Advanced analytical techniques such as High-Performance Liquid Chromatography (HPLC) and UV spectrophotometry are employed to validate active ingredient concentrations and impurity profiles. Microbial testing, endotoxin analysis, and stability studies ensure product safety and shelf life. Our quality systems are aligned with ICH, USP, and EP guidelines, ensuring compliance with global pharmaceutical standards.
Regulatory Compliance
Delwis Healthcare ensures full compliance with Good Manufacturing Practices (GMP), World Health Organization (WHO) guidelines, and ISO 9001:2015 quality management standards. Our manufacturing processes adhere to regulatory frameworks in the US, EU, and Asia-Pacific regions, including FDA, EMA, and MHRA requirements. The facility is certified under ISO 14001 for environmental management and ISO 22000 for food safety, reflecting our commitment to sustainable and safe pharmaceutical production. All documentation, including batch records and stability data, is maintained in accordance with regulatory audits and inspections.
Global Supply Capability
Delwis Healthcare is a trusted exporter with a robust international distribution network spanning over 50 countries. Our bulk supply capacity ensures timely delivery of high-quality products to meet global demand. The company maintains a reliable supply chain through partnerships with logistics providers, enabling seamless cross-border shipments. We offer flexible packaging solutions, including blister packs and bulk containers, to cater to diverse market needs. Our export capabilities are supported by compliance with international trade regulations, including HS code classification and customs documentation.
Why Choose Us
Pharmaceutical distributors, exporters, and contract manufacturing partners choose Delwis Healthcare for its expertise in combination drug manufacturing, regulatory compliance, and scalable production. Our commitment to quality, innovation, and customer support sets us apart in the industry. With a proven track record of delivering reliable bulk supplies and tailored manufacturing solutions, we ensure that clients meet market demands while maintaining compliance with global standards.
Bulk Supply Inquiry
Delwis Healthcare offers bulk supply capabilities for Tri Voglidet 0.2/2. For inquiries regarding large-scale procurement, please contact us at info@delwishealthcare.com.
FAQs
What is the manufacturing process for Tri Voglidet 0.2/2?
Tri Voglidet 0.2/2 is manufactured using direct compression techniques, with advanced coating systems to ensure sustained-release properties for Metformin.
Does Delwis Healthcare comply with WHO guidelines?
Yes, our manufacturing processes adhere to WHO guidelines and international regulatory standards for pharmaceutical production.
What packaging options are available for Tri Voglidet 0.2/2?
The product is available in 10x10 blister packs, designed for retail and hospital distribution.
Can Delwis Healthcare provide private label manufacturing services?
Yes, we offer private label manufacturing to enable clients to brand and distribute products under their own names.
What quality control measures are in place for Tri Voglidet 0.2/2?
Each batch undergoes dissolution testing, HPLC analysis, and microbial testing to ensure compliance with quality standards.
Is Tri Voglidet 0.2/2 suitable for bulk supply?
Yes, our facility is equipped for bulk production to meet global demand while maintaining product consistency.
How does Delwis Healthcare ensure regulatory compliance?
We adhere to GMP, ISO 9001, and regional regulatory frameworks, with full documentation for audits and inspections.
What is the export capability for Tri Voglidet 0.2/2?
We have a global distribution network and compliance with international trade regulations to support seamless exports.
Can Delwis Healthcare handle custom formulation requests?
Yes, we provide formulation development and customization services for pharmaceutical buyers.
How can I inquire about bulk supply of Tri Voglidet 0.2/2?
Contact us at **info@delwishealthcare.com** for detailed information on bulk procurement and supply terms.
